Mercaptopurine Anhydrous

Mercaptopurine Anhydrous

SCHEMBL11039488

S=c1nc[nH]c2nc[nH]c12.[NaH]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPAT

The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.95
HPGD P15428 4/20 0.95
SMN1; SMN2 Q16637 3/20 0.95
HBB P68871 3/20 0.95
TP53 P04637 2/20 0.95
PTGS1 P23219 2/20 0.95
TDP1 Q9NUW8 2/20 0.95
KDM4E B2RXH2 2/20 0.95
ADORA3 P0DMS8 3/20 0.52
USP2 O75604 1/20 0.52
MAPK3 P27361 1/20 0.52
XDH P47989 1/20 0.52
PAX8 Q06710 1/20 0.52
RXFP1 Q9HBX9 4/20 0.44
PRNP P04156 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
ADORA2A P29274 4/20 0.38
PDE4A P27815 3/20 0.38
PDE4B Q07343 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mercaptopurine Anhydrous SCHEMBL1176622 0.98 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL19209580 0.95 ALDH1A1 (0.95) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL4447613 0.81 ALDH1A1 (0.69) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL12476114 0.77 ALDH1A1 (0.62) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL4582542 0.74 ALDH1A1 (0.57) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL1498067 0.74 ALDH1A1 (0.57) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL5323979 0.74 ALDH1A1 (0.57) ALDH1A1HPGDSMN1; SMN2HBBTP53
Mercaptopurine Anhydrous SCHEMBL14691260 0.72 ALDH1A1 (0.54) ALDH1A1HPGDSMN1; SMN2HBBTP53
Hypoxanthine SCHEMBL122844 0.71 ALDH1A1 (0.52) ALDH1A1HPGDSMN1; SMN2HBBTP53
Thioguanine SCHEMBL31327802 0.69 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2HBBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865983-A Indane compound, preparation method and medical application thereof 中国药科大学 2024-04-12 CN disclosed
CN-117865984-A Naphthalene compound and preparation method and medical application thereof 中国药科大学 2024-04-12 CN disclosed
CN-112812111-A Benzothiazole compound and medical application thereof 中国药科大学 2021-05-18 CN disclosed
CN-112608320-A Piperidine compound and preparation method and medical application thereof 中国药科大学 2021-04-06 CN disclosed
US-10376649-B2 Drug delivery device for delivery of two or more independently user selectable multiple doses of medicaments with user operable variable dose locking mechanisms WOCKHARDT LIMITED (IN) 2019-08-13 US disclosed
EP-3212257-A1 A DRUG DELIVERY DEVICE FOR DELIVERY OF TWO OR MORE INDEPENDENTLY USER SELECTABLE MULTIPLE DOSES OF MEDICAMENTS WITH USER OPERABLE VARIABLE DOSE LOCKING MECHANISMS Wockhardt Limited (IN) 2017-09-06 EP disclosed
US-20170239422-A1 A drug delivery device for delivery of two or more independently user selectable multiple doses of medicaments with user operable variable dose locking mechanisms WOCKHARDT LIMITED (IN) 2017-08-24 US disclosed
WO-2016067179-A1 A DRUG DELIVERY DEVICE FOR DELIVERY OF TWO OR MORE INDEPENDENTLY USER SELECTABLE MULTIPLE DOSES OF MEDICAMENTS WITH USER OPERABLE VARIABLE DOSE LOCKING MECHANISMS WOCKHARDT LIMITED (IN) 2016-05-06 WO disclosed
EP-0120907-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY Aston Molecules Limited (GB) 1984-10-10 EP disclosed
WO-1984001506-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY UNIV BIRMINGHAM (GB) 1984-04-26 WO disclosed